https://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Reports-Top-line-Phase-IIa-Data-for-IW-1973-Demonstrating-Positive-Cardiovascular-Metabolic-and-Endothelial-Effects/default.aspx
Ironwood Pharmaceuticals is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients.
- December 4, 2017